Product Images Desvenlafaxine
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 7 images provide visual information about the product associated with Desvenlafaxine NDC 68071-2704 by Nucare Pharmaceuticals,inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
pdp - 68071 2704 3
This is a medication label for Desvenlafaxine 50mg tablets. It contains information such as the lot number, manufacturer NDC, exp. date, and serial number. The label also includes a warning to keep the medication out of reach of children, and a note to store it at a controlled temperature of 68-77°F. It provides instructions to see the manufacturer's label for a full list of ingredients, and to call a doctor for medical advice about side effects, with a phone number to report side effects to the FDA.*
Figure 1 - desvenlafaxine figure1
The text provides information on the impact of renal and hepatic impairment and population description on PK. The geometric mean ratios (90% CI) of Cmax and AUC for different levels of renal and hepatic impairment are given. Also, the impact of age and gender on Cmax and AUC is presented. Therefore, the text might be useful in understanding the pharmacokinetics of a particular drug in different populations and conditions.*
Figure 2 - desvenlafaxine figure2
This text provides information on the change due to PK and CYP3A4 inhibitors such as ketoconazole. The geometric mean ratio with a 30% confidence level is also mentioned. There is information on the change in Cmax (maximum concentration) and AUC (area under the curve) for ketoconazole compared to the reference. However, as no context or further information is given, it is not clear what study or drug is being referred to.*
Figure 3 - desvenlafaxine figure3
Figure 4 - desvenlafaxine image4
Figure 5 - desvenlafaxine image5
The text shows a chart that indicates the estimated proportion of patients with a relapse and time to relapse in days from randomization. The chart compares Desvenlafaxine Extended-Release Tablets against Placebo. No additional information is available for interpretation.*
Structure - desvenlafaxine structure1
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
